A phase II clinical trial of stereotactic radiosurgery versus radiofrequency ablation in the treatment of inoperable primary liver cancer in specific sites
Prior to implementing any trial-related procedures, written informed consent must be signed;
Age ≥ 18 years and ≤ 75 years;
Child-Pugh score ≤ 7;KPS score ≥ 70;
The patient must be clearly diagnosed with hepatocellular carcinoma, usually confirmed through imaging (CT, MRI) or histological examination (biopsy);
Possible surgical intervention;
Presence of other serious comorbidities, such as uncontrolled cardiovascular diseases, pulmonary diseases, or dysfunction of other organs, where the overall health status is poor and may result in treatment intolerance;
Severe liver dysfunction exceeding the specific criteria defined in the trial;
Other malignancies diagnosed within 5 years prior to the first treatment or at the time of diagnosis of hepatocellular carcinoma;
Tianjin Medical University Cancer Institute and Hospital
Lead sponsor